These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29497001)

  • 1. The National Oncologic PET Registry (NOPR): A Monumental Effort by a Few Leaders.
    Czernin J
    J Nucl Med; 2018 Mar; 59(3):379. PubMed ID: 29497001
    [No Abstract]   [Full Text] [Related]  

  • 2. The National Oncologic PET Registry (NOPR): design and analysis plan.
    Hillner BE; Liu D; Coleman RE; Shields AF; Gareen IF; Hanna L; Stine SH; Siegel BA
    J Nucl Med; 2007 Nov; 48(11):1901-8. PubMed ID: 17942807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The National Oncology PET Registry (NOPR): A monumental effort by a few leaders.
    Czernin J
    J Nucl Med; 2018 Jan; ():. PubMed ID: 29371409
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry.
    Hillner BE; Siegel BA; Shields AF; Duan F; Gareen IF; Hanna L; Coleman RE
    Mol Imaging Biol; 2011 Feb; 13(1):161-5. PubMed ID: 21080232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.
    Hillner BE; Tosteson AN; Tosteson TD; Wang Q; Song Y; Hanna LG; Siegel BA
    J Nucl Med; 2013 Dec; 54(12):2024-31. PubMed ID: 24221994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
    Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
    Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.
    Lindsay MJ; Siegel BA; Tunis SR; Hillner BE; Shields AF; Carey BP; Coleman RE
    AJR Am J Roentgenol; 2007 Apr; 188(4):1109-13. PubMed ID: 17377055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
    J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The National Oncologic PET Registry: lessons learned for coverage with evidence development.
    Tunis S; Whicher D
    J Am Coll Radiol; 2009 May; 6(5):360-5. PubMed ID: 19394577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Coleman RE
    J Nucl Med; 2014 Apr; 55(4):574-81. PubMed ID: 24578240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospice Admission and Survival After
    Gareen IF; Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Siegel BA
    J Nucl Med; 2018 Mar; 59(3):427-433. PubMed ID: 29284672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
    Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hunt E; Coleman RE
    J Nucl Med; 2008 Dec; 49(12):1928-35. PubMed ID: 18997054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2014 Cassen Lecture: What have we learned from the National Oncologic PET Registry?
    Siegel BA
    J Nucl Med; 2014 Dec; 55(12):9N-15N. PubMed ID: 25453061
    [No Abstract]   [Full Text] [Related]  

  • 14. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hanna L; Stine SH; Coleman RE
    Cancer; 2009 Jan; 115(2):410-8. PubMed ID: 19016303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [National uro-oncologic registry].
    Actas Urol Esp; 1993 Apr; 17(4):6 p.. PubMed ID: 8342424
    [No Abstract]   [Full Text] [Related]  

  • 16. A broader importance of NOPR to the future of nuclear imaging.
    Hillman BJ
    J Nucl Med; 2012 May; 53(5):677-8. PubMed ID: 22442104
    [No Abstract]   [Full Text] [Related]  

  • 17. PET and PET/CT reports: observations from the National Oncologic PET Registry.
    Coleman RE; Hillner BE; Shields AF; Duan F; Merlino DA; Hanna LG; Stine SH; Siegel BA
    J Nucl Med; 2010 Jan; 51(1):158-63. PubMed ID: 20008997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intended Versus Inferred Treatment After
    Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Gareen I; Siegel BA
    J Nucl Med; 2018 Mar; 59(3):421-426. PubMed ID: 29191854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.
    Hillner BE; Siegel BA; Hanna L; Shields AF; Duan F; Gareen IF; Quinn B; Coleman RE
    J Nucl Med; 2012 May; 53(5):831-7. PubMed ID: 22448033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Quinn B; Coleman RE
    J Nucl Med; 2014 Jul; 55(7):1054-61. PubMed ID: 24819422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.